中恒集团 (600252.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−18.3x

Market Cap

CNY 6.94B

MomentumView details →

1D Return

−1.80%

YTD Return

−18.98%

RSI (14)

47.3

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−18.3x

Market Cap

CNY 6.94B

RSI (14)

47.3

MomentumView details →

1D Return

−1.80%

YTD Return

−18.98%

ProfitabilityView details →

Gross Margin

46.80%

Net Margin

−25.80%

EBITDA Margin

−22.84%

ROE (TTM)

−7.75%

ROA (TTM)

−3.97%

Asset Turnover

0.16x

GrowthView details →

Revenue YoY

−15.24%

EPS YoY

−6.40%

FCF YoY

−89.85%

Revenue CAGR 3Y

−13.63%

EPS CAGR 3Y

−2.23%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.36x

Current Ratio

2.13x

Quick Ratio

1.88x

Div Yield

—

Div Rate

—

Div Growth 1Y

+0.00%

Financials snapshotView financials →

Revenue (TTM)

1.58B

Net Income (TTM)

−408.05M

Op. CF (TTM)

67.83M

Latest newsMore news →

Zhongheng Group announced its first share repurchase of 4.7 million shares on August 31, 2026, with a cumulative repurchase amount of 10.851 million yuan, under a plan to repurchase 100-200 million yuan of shares to reduce registered capital.5d ago

Zhongheng Group's board approved extending the operating term of its consolidated partnership Guangxi Defu from June 30, 2026 to May 30, 2027, subject to partner meeting approval.19d ago

Similar companies

中牧股份600195.SH China Traditional Chinese Medicine Holdings Co. Limited00570.HK 康缘药业600557.SH 百克生物688276.SH CanSino Biologics Inc.06185.HK 阳光诺和688621.SH Find similar companies →

Latest newsMore news →

Zhongheng Group announced its first share repurchase of 4.7 million shares on August 31, 2026, with a cumulative repurchase amount of 10.851 million yuan, under a plan to repurchase 100-200 million yuan of shares to reduce registered capital.5d ago Zhongheng Group's board approved extending the operating term of its consolidated partnership Guangxi Defu from June 30, 2026 to May 30, 2027, subject to partner meeting approval.19d ago